TB-500 safety questions
The safety questions deserve direct answers, even where the honest answer leaves a blank in the file.
What are the side effects of TB-500?
The fragment lacks a controlled human safety study from which to build a dependable side-effect list. The online reports described on the effects page are anecdotal accounts, not clinical evidence, and include local reactions, tiredness, headache and nausea.
Full-length thymosin beta-4 was well tolerated in a short Phase 1 intravenous study in healthy volunteers. Its uncommon mild or moderate adverse events and absence of serious adverse events describe that study’s material and setting. I cannot use them to settle the fragment’s safety.
Does TB-500 cause cancer?
A human cancer risk has not been established or quantified for TB-500. The concern comes from full-length thymosin beta-4’s association with tumour metastasis and angiogenesis in preclinical work and its overexpression in human pancreatic cancer cells in vitro.
The same capacity to support cell movement and blood-vessel growth that attracts repair research could support tumour progression. I give that possibility serious weight while leaving its magnitude in people unanswered. A cell-line result cannot supply a personal probability.
Is TB-500 safe for long-term use?
Long-term human safety for the fragment remains unknown. The 2026 review of unapproved peptide therapies describes scarce rigorous human safety data and potential for serious harm. The short-term full-length study resolves only a limited question.
Bleeding and surgical risks are theoretical concerns in this case, with no fragment study measuring them. Pregnancy, breastfeeding and growing bodies also lack human fragment safety data. I see an unfinished safety assessment wherever these questions arise.
What is the difference between TB-500 and BPC-157?
TB-500 is the synthetic actin-binding fragment of thymosin beta-4; BPC-157 is an unrelated peptide based on a substance from gastric juice. The 2026 sports-medicine review discusses both among unapproved peptides. Their shared presence in recovery discussions supplies no evidence for treating them as interchangeable or combining them.
The chemical identity of TB-500 is anchored by the Ac-LKKTETQ detection work. TB in the name refers to thymosin beta. I prefer that modest explanation of the name to giving the designation a larger biological meaning.
Does TB-500 increase hair growth?
Human hair growth from the TB-500 fragment remains unproved, and community hair accounts are anecdotal and sometimes involve other interventions.
Is TB-500 legal or FDA approved?
TB-500 has no FDA-approved medical use. On FDA's page current as of April 22, 2026, the nomination is recorded as withdrawn, with the safety rationale retained and TB-500 no longer in Category 2. FDA supplies no removal date. The legal file explains the unresolved compounding question. WADA prohibits TB-500 and thymosin beta-4 in and out of competition.